Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So
11:04am, Friday, 16'th Jan 2026
Hedge funds don't need headlines to move — they need inflection points. ImmunityBio Inc (NASDAQ: IBRX) just delivered one.
ImmunityBio shares rise on positive CAR-NK trial results in Waldenström lymphoma
10:48am, Friday, 16'th Jan 2026
Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses in patients treated with its off-the-shelf CD19 CAR-
Nasdaq, Dow Jones little changed as TSMC settles tech jitters
08:15am, Friday, 16'th Jan 2026
1:15pm: Market movers Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial in BCG-naïve non-muscle-invasive bl
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinica
This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today.
05:52am, Friday, 16'th Jan 2026
The shares have climbed on every trading day so far in 2026. The streak looks set to continue.
U.S. stock futures rose on Friday following Thursday's positive close. Futures of major benchmark indices were higher.
ImmunityBio shares rise on positive CAR-NK trial results in Waldenström lymphoma
05:45am, Friday, 16'th Jan 2026
Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses in...
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%
05:27pm, Thursday, 15'th Jan 2026
On Jan. 15, 2026, investors took note of Anktiva's explosive sales ramp, its geographic expansion potential, and a possible new indication.
ImmunityBio: Why I Am Upgrading To A Buy For 2026
12:50pm, Thursday, 15'th Jan 2026
ImmunityBio is upgraded to Buy for 2026, reflecting improving Anktiva data and potential label expansions in NMIBC and NSCLC. IBRX reported 2025 product revenue of $113m, up 700% year-on-year, but los
ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug
12:43pm, Thursday, 15'th Jan 2026
ImmunityBio, Inc. (NASDAQ: IBRX) shares are up on Thursday as the company is reporting continued execution and sales momentum, with a significant increase in preliminary net product revenue.
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, announced today preliminary select operational results for the f
Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
08:30am, Wednesday, 14'th Jan 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted approval of
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted accelerated
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) clinica
